Summary: Listen to our takeaways from large-cap pharma earnings, Oakmark’s strength in stock-picking, and why we raised Intuit’s fair value estimate.
Summary: Listen to our takeaways from large-cap pharma earnings, Oakmark’s strength in stock-picking, and why we raised Intuit’s fair value estimate.